Navigation Links
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
Date:3/12/2008

MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it would need to conduct additional clinical studies to address questions from the Committee for Medicinal Products for Human Use (CHMP) regarding the risk-benefit profile of desvenlafaxine as a treatment for vasomotor symptoms. As a result, Wyeth voluntarily withdrew its application for European Marketing Authorisation for desvenlafaxine for the treatment of vasomotor symptoms (hot flashes) associated with menopause.

"We believe that desvenlafaxine can provide women with a non-hormonal option to treat vasomotor symptoms (VMS), and Wyeth remains committed to developing the molecule for this indication," says Gary L. Stiles, M.D., Executive Vice President and Chief Medical Officer, Wyeth Pharmaceuticals. "Some of the questions raised by the CHMP can be addressed with our planned clinical trials, including the 12-month study Wyeth is initiating with post- menopausal women early this year. The Company also is considering whether to conduct additional studies."

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include W
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
2. Genetic research unveils common origins for distinct clinical diagnoses
3. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
4. Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
5. Sensor necklace aims to increase elderly and clinical trial participant drug compliance
6. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
7. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
8. Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer
9. Clinical depression raises risk of death for heart attack patients years after attack
10. IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines
11. Skin Friendly Releases Clinically Proven Hypoallergenic Anti-Bacterial Barrier Lotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... (PRWEB) September 03, 2014 Recently, BambooIndustry.com, ... its new range of strand woven bamboo floors ... more clients and show its appreciation to the frequent ... products. , In addition to strand woven floors, ... clients, including hand scraped floors, click strand woven floors, ...
(Date:9/2/2014)... Atlanta, Ga. (PRWEB) September 02, 2014 ... hosted by, respectively, top-industry professionals Carey Lewis ... each person auditioning, seeking those who have the desire ... chosen for a callback, performers could be invited to ... SHINE convention. , Charlotte, NC – Saturday, Sept. 6, ...
(Date:9/2/2014)... 2014 The Wm. Jennings Bryan Dorn Veterans ... town hall meeting for Veterans and their families on September ... fair to provide Veterans with valuable healthcare and benefit information,” ... will provide a forum where we can gather important input ... outreach fair will be held 4:45 p.m. to 5:45 p.m. ...
(Date:9/2/2014)... In a large population-based study of randomly selected ... impairment (MCI) occurred twice more often in individuals ... strong association was only observed in middle-aged participants ... the association vanished. This study is published in ... The concept of MCI describes an intermediate state ...
(Date:9/2/2014)... Operators in the Community Services industry ... care and counsel for those in need. In 2014-15, ... derive $39.4 billion in revenue, which includes a combination ... five years through 2014-15, the subdivision is forecast to ... of 4.1% in 2014-15. , As the population ages ...
Breaking Medicine News(10 mins):Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Using tiny gold particles embedded with dyes, researchers have ... of a living animal. These tools may allow doctors ... , Studded with antibody fragments called ScFv peptides that ... after their injection into a mouse. When illuminated with ...
... simple steps can help you cope , , SATURDAY, Dec. 22 ... of joy and celebration for many, it can trigger holiday ... to holiday blues, there are things you can do to ... Mood Disorders Program at the Jefferson Medical College of Thomas ...
... Kansas Hospital Offers Tips to Guard Against Influenza as ... ... While it may be too late to,purchase certain must-have gifts ... shot. The World Health Organization (WHO) and,National Respiratory and Enteric Virus ...
... PCYC ) today announced that it has received a ... for the company,s,new drug application (NDA) for Xcytrin(R) (motexafin ... (NSCLC) patients with brain,metastases. The NDA for use of ... filed with the FDA in April 2007., According ...
... indications than any other ... drug-eluting stent, ... announced today that its TAXUS(R) Liberte(TM),paclitaxel-eluting coronary stent system has received ... submitted,data showing the TAXUS Liberte stent has benefited diabetic patients with,coronary ...
... considered, protected, HARRISBURG, Pa., Dec. 21 To ... Joel,Ario today announced that the Insurance Department will hold ... the proposed consolidation of,Independence Blue Cross and Highmark Inc., ... would be protected in,any transaction of this type, so ...
Cached Medicine News:Health News:Gold nanoparticle probes may allow earlier cancer detection 2Health News:Gold nanoparticle probes may allow earlier cancer detection 3Health News:Maintaining Routine Can Chase Holiday Blues Away 2Health News:Attention Last-Minute Shoppers: Flu Shots Still Available 2Health News:Attention Last-Minute Shoppers: Flu Shots Still Available 3Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 2Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 5Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2
(Date:9/2/2014)... 2, 2014 According to the ... Pre-packed, Analytical, Preparative), by Material (Metal, Glass, Plastic), by ... Forecast to 2018", published by MarketsandMarkets, the Chiral Chromatography ... is poised to grow at a CAGR of 5.2% ... Browse 90 market data tables and 15 ...
(Date:9/2/2014)... ALISO VIEJO, Calif. , Sept. 2, 2014  Avanir ... company management will present an overview of the company at ... York . , Presentation date: Tuesday September ... A live webcast and 30-day archive of ... About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, ...
(Date:9/2/2014)... 2014  EMD Serono, Inc., a subsidiary of Merck ... that Drew Young has joined the company ... capacity, he will be responsible for leading the strategic ... future products.   Bringing more than 20 years ... efforts at pharmaceutical and biotech companies, Mr. Young comes ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
... Chrome-plated metal frames ... ensures optimal cleanliness and ... stools come with user-friendly ... height adjustment. Fixed footring ...
... The ideal modular cleanroom for ... applications that require cleanliness (to Class ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Inquire...
Medicine Products: